Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol
Drug ID BADD_D02219
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
Marketing Status Prescription; Discontinued
ATC Code C07AA06; S01ED01
DrugBank ID DB00373
KEGG ID D00378
MeSH ID D013999
PubChem ID 33624
TTD Drug ID D05UVD
NDC Product Code 17478-365; 76478-002; 17478-366; 76478-001; 17478-189
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C13H24N4O3S
CAS Registry Number 26839-75-8
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.001536%
Hypothermia12.05.03.001; 08.05.01.0030.001097%
Hypoxia22.02.02.0030.000439%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Intermittent claudication24.04.03.001--Not Available
Intraocular pressure increased13.07.04.0020.002853%Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.0040.000658%
Laryngospasm22.04.02.002--
Lethargy17.02.04.003; 19.04.04.004; 08.01.01.0080.000878%
Libido decreased19.08.03.001; 21.03.02.005--
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.0040.001975%Not Available
Macular oedema06.04.06.005--Not Available
Metabolic acidosis14.01.01.0030.000439%Not Available
Mood swings19.04.03.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000439%
Myalgia15.05.02.001--
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.001--
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Ocular hyperaemia06.04.05.0040.002414%Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages